Marshall Wace North America Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$221M |
| 2 |
GoDaddy
GDDY
|
+$159M |
| 3 |
Cigna
CI
|
+$135M |
| 4 |
Pfizer
PFE
|
+$132M |
| 5 |
HOLX
Hologic
HOLX
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$156M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Microsoft
MSFT
|
+$126M |
| 4 |
McDonald's
MCD
|
+$121M |
| 5 |
Danaher
DHR
|
+$107M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.95% |
| 2 | Technology | 21.4% |
| 3 | Consumer Discretionary | 12.43% |
| 4 | Industrials | 11.77% |
| 5 | Financials | 6.59% |
Similar funds
Marshall Wace North America's Q4 2019 Portfolio in Review
As of Q4 2019, Marshall Wace North America held 1,778 positions worth $20.7B, up 18% from $17.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace North America deployed $1.47B of net new capital in Q4 2019, opening 496 new positions and adding to 377 existing holdings. Its largest new stake was Deere & Co: 519,053 shares worth $89.9M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 26% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $156M trimmed.
- Marshall Wace North America's largest Q4 2019 buy was Deere & Co: 519,053 shares worth $89.9M.
- Marshall Wace North America added most to HCA Healthcare in Q4 2019, an estimated $221M increase.
- Marshall Wace North America's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $156M.
- Marshall Wace North America fully exited McDonald's in Q4 2019, selling an estimated $121M.
- Marshall Wace North America's ten largest holdings make up 16% of its $20.7B portfolio in Q4 2019.
- Marshall Wace North America opened 496 new positions and closed 524 in Q4 2019.
- Marshall Wace North America's portfolio value rose 18% quarter-over-quarter to $20.7B.
Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.